Pneumonitis Related to Melanoma Immunotherapy

ABSTRACTSeveral regimens of immunotherapy have recently proven successful for multiple cancers, due to increased survival and quality of life. Rarely, immunotherapy with anti-programmed cell death protein 1 and programmed death-ligand 1 antibodies across cancer may cause immune-related pulmonary tox...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2019-06, Vol.44 (6), p.e392-e393
Main Authors: García-Gómez, Francisco Javier, Álamo-de la Gala, María Carmen, de la Riva-Pérez, Pablo Antonio, de la Cruz-Merino, Luis, de la Cinta Calvo-Morón, María
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTSeveral regimens of immunotherapy have recently proven successful for multiple cancers, due to increased survival and quality of life. Rarely, immunotherapy with anti-programmed cell death protein 1 and programmed death-ligand 1 antibodies across cancer may cause immune-related pulmonary toxicity, with a low overall incidence, being particularly low among patients with melanoma and highest among individuals with lung cancer. In this vein, pulmonary toxicity is staged at 4 degrees according to the severity of the clinic and radiological findings, and its management is based on suppression of immunotherapy and administration of glucocorticoids. We report a case of pulmonary toxicity related to melanoma immunotherapy observed by F-FDG PET/CT.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000002549